Respiratory DiseaseVOC-COMPARENCT06020521
Analysis of Volatile Organic Compounds in Expired Air in Healthy Volunteers: Comparison of Three Mass Spectrometry Techniques for the Characterization of Volatolome in Clinical Studies
A study testing Three spectrometry differents technics in people with Respiratory Disease, run by Hopital Foch at 1 site in France.
Trial summary
A major obstacle in precision medicine is the unavailability of biomarkers that are easy to access, non-invasive, measurable with high-performance techniques, fast, easy to use, reproducible, inexpensive and easily deployable on a large scale. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Respiratory Disease
- What is being tested?
- Three spectrometry differents technics
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteFrance
- Study dates
- 8 Jul 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy volunteer
- At least 18 years old
- Perfect command of the French language
- Signature of an informed consent form
- Affiliated to a health insurance plan
Who cannot join
- Pregnant women
- People with known pathology(ies)
- Active smoking
- Deprived of liberty or under guardianship
Trial locations and contacts
1 site in 1 country.
About this study
A major obstacle in precision medicine is the unavailability of biomarkers that are easy to access, non-invasive, measurable with high-performance techniques, fast, easy to use, reproducible, inexpensive and easily deployable on a large scale. The analysis of exhaled air (volatolomics) is an "omics" approach devoted to the analysis of volatile organic compounds (VOCs) eliminated by the pulmonary route with real-time detection, at the patient's bedside. The reference technology for the analysis of VOCs is mass spectrometry (MS). Several types of mass spectrometers can be used, and, in the absence of a consensual and standardized method, have practical methods for carrying out different analyzes which also lead to the generation of specific signals whose nature, complexity and exhaustiveness of information generated are heterogeneous. The clinical studies carried out to date use one of the analytical techniques available, without the choice necessarily being guided by objective factors. The objective of this study is to fill this gap and compare the information obtained by three mass spectrometry techniques available to our team (proton transfer reaction - mass spectrometry (PTR-MS), Soft Ionization by Chemical Reaction in Transfer (SICRIT) , two-dimensional gas chromatography-mass spectrometry (GCxGC-MS)) for volatolome analysis. The comparative analysis of the different signals will make it possible to determine the interests and limits of each technique and thus to direct preferentially towards one, the other, or combinations of them for the realization of future clinical studies. One of the main challenges also consists in establishing the concordance of the signals generated by the different technological approaches, some employing prior chromatographic separation, others not, and some employing soft ionization methods while those of others are on the contrary hard. Thus, the availability of datasets obtained on the same population with these complementary approaches will allow significant progress for the identification of the COVs of interest in clinical studies, beyond the simple comparison of the analytical performances of the different methods.
Read the detailed description
Precision medicine, or personalized medicine or individualized medicine, represents an important source of hope for alleviating the social and economic burden of severe pathologies. There is no commonly accepted definition of the notion of "personalized medicine". However, according to the European Council, personalized medicine is a medical model that relies on the characterization of people's phenotypes and genotypes (e.g. through molecular profiling, medical imaging, lifestyle information) to offer the right therapeutic strategy to the right person at the right time and/or to establish the existence of a predisposition to a disease and/or to ensure targeted and timely prevention. Personalized medicine is linked to the broader notion of "patient-centred care", which takes into account the general need for health systems to better meet the needs of patients. Advances in research have made it possible to develop "omic" signatures of therapeutic responses to certain cancers or rare diseases. However, if a few omic or cellular biomarkers have been developed, they remain today insufficient and too complex to foresee their generalization for the individualized treatment of patients. Thus, today there is significant potential for the development of precision medicine for severe pathologies. A major obstacle in precision medicine is the unavailability of biomarkers that are easy to access, non-invasive, measurable with high-performance techniques, fast, easy to use, reproducible, inexpensive and easily deployable on a large scale.
The analysis of exhaled air (volatolomics) is derived from the latest "omics" technology, metabolomics, devoted to the analysis of small molecules in the body, and allows real-time detection, sick bed, volatile organic compounds (VOCs) eliminated through the lungs. Thousands of VOCs have been identified in exhaled air following infectious, inflammatory or pathological events with examples in the field of infectious diseases for the diagnosis of tuberculosis, invasive fungal infections, bacterial colonization of the airways or ventilator-associated pneumonia in intensive care patients . For viral infections, animal models of influenza infections and clinical studies in patients with chronic obstructive pulmonary disease also suggest the benefit of VOC analysis . In this infectious context, the "respiratory fingerprint" detected reflects a mixture of metabolites of microbial origin, direct biomarkers of the presence of pathogenic agents, and metabolites generated by the host in response to the infection. Thus, the analysis of exhaled air, the main advantages of which are totally non-invasive sampling and the instantaneous analysis allowed by certain technologies (result in a few minutes) could be used for diagnosis, large-scale screening, surveillance of infections and prediction of response to treatment. The technological challenges for its realization are linked to the great chemical diversity of the VOCs to be studied and the particularly low abundance of many of them.
The reference technology for the analysis of VOCs is mass spectrometry (MS), which uses instruments consisting of - an ionization source whose function is to ionize the VOCs contained in exhaled air, - an analyzer which sorts the ions formed according to their mass to charge ratio (m/z) and - a detector which allows the quantitative analysis of the m/z signals of a sample . Several types of mass spectrometers can be used, and, in the absence of a consensual and standardized method, have practical methods for carrying out different analyzes which also lead to the generation of signals specific to each of them, the nature, the complexity and the completeness of the information contained being heterogeneous. Each type of instrument has advantages and disadvantages in terms of ease of sampling, speed of analysis, completeness of information and technical and analytical constraints for carrying out the analyses. For example, some instruments such as proton transfer reaction mass spectrometers (PTR-MS) or those using soft ionization by chemical transfer reaction (SICRIT) are relevant for perform measurements online and in real time, without storing a sample of exhaled air but vary by their mode of ionization and the resolution of the associated detectors. However, their level of information generated does not generally allow VOCs to be identified (soft ionization, absence of chromatographic separation, etc.). Indeed, once a signature of VOCs (characterized by their m/z) is discovered, their formal chemical identification is then the critical and obligatory step to improve knowledge on the physiology and regulatory processes of VOCs as well as to set up and clinically validate specific quantitative measurement methods based on portable technologies (sensors, etc.). Two-dimensional gas chromatography coupled with mass spectrometry (GCxGC-MS) is the most advanced technology at present for this purpose, combining two chromatographic columns with complementary stationary phases and ionization of VOCs by electron impact before MS detection. Compounds coeluting in conventional gas chromatography can be separated by GCxGC, and several teams have published proof-of-concept studies using GCxGC-MS for breath biomarker discovery for lung cancer diagnosis , tuberculosis or severe asthma phenotyping . One of the main challenges consists in establishing the concordance of the signals generated by the different technological approaches, some employing a preliminary chromatographic separation, others not, and some employing soft ionization methods whereas those of the others are on the contrary hard. Thus, the availability of datasets obtained on the same population with these complementary technological approaches will allow significant progress for the identification of the COVs of interest in clinical studies, beyond the simple comparison of the analytical performances of the different methods.
- Conditions
- Respiratory Disease
- Being tested
- Three spectrometry differents technics
- Keywords
- precision medicine,, biomarkers, analysis of exhaled air (volatolomics), mass spectrometry
- Medical subject headings
- Respiration Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Three spectrometry differents technicsOther
Collection of expired air as follows:
- For online mass spectrometry techniques (PTR-MS and SICRIT)
- For offline mass spectrometry (GCxGC-MS)
Performing volatolome analyses:
- By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes
- By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes.
| Study group | Role | What they receive |
|---|---|---|
| Group of healthy volunteers | Other | This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required. Receives: Other: Three spectrometry differents technics |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare informations obtained by three different spectrometry techniques
Compare the information obtained by three mass spectrometry techniques (PTR-MS, SICRIT, GCxGC-MS) for the analysis of volatolome during clinical studies
Measured: one day
Secondary outcomes (3)
1- Compare sampling techniques
Compare the information obtained by three mass spectrometry techniques (PTR-MS, SICRIT, GCxGC-MS) for the analysis of volatolome during clinical studies
Measured: one day
2-Compare the profile of VOCs
Compare the profile of VOCs of differents patients
Measured: one day
Determine the average time needed to perform each type of sample and associated analyzes
Determine the average time needed to perform each type of sample and associated analyzes
Measured: one day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2023
- Study start8 Jul 2023
- Primary completion30 Aug 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required.
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopital Foch
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06020521
- Sponsor's protocol ID
- 2023_0020
- Acronym
- VOC-COMPARE
- Status last verified
- May 2025
- First submitted
- 28 Aug 2023
- Last updated
- 28 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Roquencourt C, Lamy E, Hunzinger N, Salvator H, Devillier P, Bardin E, Grassin-Delyle S. Soft ionization by chemical reaction in transfer-high-resolution mass spectrometry for clinical exhaled breath profiling. Anal Bioanal Chem. 2026 Jun;418(11):3227-3238. doi: 10.1007/s00216-026-06425-1. Epub 2026 Mar 15.
PubMed 41832327
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Volatile Organic Compounds in Expired Air in Healthy Volunteers: Comparison of Three Mass Spectrometry Techniques for the Characterization of Volatolome in Clinical Studies
- ClinicalTrials.gov ID
- NCT06020521
- Acronym / sponsor ID
- VOC-COMPARE / 2023_0020
- Conditions
- Respiratory Disease
- Keywords
- precision medicine,, biomarkers, analysis of exhaled air (volatolomics), mass spectrometry
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Hopital FochUniversity, hospital or other
- Study start
- 8 Jul 2023 (actual)
- Primary completion
- 30 Aug 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 31 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A major obstacle in precision medicine is the unavailability of biomarkers that are easy to access, non-invasive, measurable with high-performance techniques, fast, easy to use, reproducible, inexpensive and easily deployable on a large scale. The analysis of exhaled air (volatolomics) is an "omics" approach devoted to the analysis of volatile organic compounds (VOCs) eliminated by the pulmonary route with real-time detection, at the patient's bedside. The reference technology for the analysis of VOCs is mass spectrometry (MS). Several types of mass spectrometers can be used, and, in the absence of a consensual and standardized method, have practical methods for carrying out different analyzes which also lead to the generation of specific signals whose nature, complexity and exhaustiveness of information generated are heterogeneous. The clinical studies carried out to date use one of the analytical techniques available, without the choice necessarily being guided by objective factors. The objective of this study is to fill this gap and compare the information obtained by three mass spectrometry techniques available to our team (proton transfer reaction - mass spectrometry (PTR-MS), Soft Ionization by Chemical Reaction in Transfer (SICRIT) , two-dimensional gas chromatography-mass spectrometry (GCxGC-MS)) for volatolome analysis. The comparative analysis of the different signals will make it possible to determine the interests and limits of each technique and thus to direct preferentially towards one, the other, or combinations of them for the realization of future clinical studies. One of the main challenges also consists in establishing the concordance of the signals generated by the different technological approaches, some employing prior chromatographic separation, others not, and some employing soft ionization methods while those of others are on the contrary hard. Thus, the availability of datasets obtained on the same population with these complementary approaches will allow significant progress for the identification of the COVs of interest in clinical studies, beyond the simple comparison of the analytical performances of the different methods.
Detailed description
Precision medicine, or personalized medicine or individualized medicine, represents an important source of hope for alleviating the social and economic burden of severe pathologies. There is no commonly accepted definition of the notion of "personalized medicine". However, according to the European Council, personalized medicine is a medical model that relies on the characterization of people's phenotypes and genotypes (e.g. through molecular profiling, medical imaging, lifestyle information) to offer the right therapeutic strategy to the right person at the right time and/or to establish the existence of a predisposition to a disease and/or to ensure targeted and timely prevention. Personalized medicine is linked to the broader notion of "patient-centred care", which takes into account the general need for health systems to better meet the needs of patients. Advances in research have made it possible to develop "omic" signatures of therapeutic responses to certain cancers or rare diseases. However, if a few omic or cellular biomarkers have been developed, they remain today insufficient and too complex to foresee their generalization for the individualized treatment of patients. Thus, today there is significant potential for the development of precision medicine for severe pathologies. A major obstacle in precision medicine is the unavailability of biomarkers that are easy to access, non-invasive, measurable with high-performance techniques, fast, easy to use, reproducible, inexpensive and easily deployable on a large scale.
The analysis of exhaled air (volatolomics) is derived from the latest "omics" technology, metabolomics, devoted to the analysis of small molecules in the body, and allows real-time detection, sick bed, volatile organic compounds (VOCs) eliminated through the lungs. Thousands of VOCs have been identified in exhaled air following infectious, inflammatory or pathological events with examples in the field of infectious diseases for the diagnosis of tuberculosis, invasive fungal infections, bacterial colonization of the airways or ventilator-associated pneumonia in intensive care patients . For viral infections, animal models of influenza infections and clinical studies in patients with chronic obstructive pulmonary disease also suggest the benefit of VOC analysis . In this infectious context, the "respiratory fingerprint" detected reflects a mixture of metabolites of microbial origin, direct biomarkers of the presence of pathogenic agents, and metabolites generated by the host in response to the infection. Thus, the analysis of exhaled air, the main advantages of which are totally non-invasive sampling and the instantaneous analysis allowed by certain technologies (result in a few minutes) could be used for diagnosis, large-scale screening, surveillance of infections and prediction of response to treatment. The technological challenges for its realization are linked to the great chemical diversity of the VOCs to be studied and the particularly low abundance of many of them.
The reference technology for the analysis of VOCs is mass spectrometry (MS), which uses instruments consisting of - an ionization source whose function is to ionize the VOCs contained in exhaled air, - an analyzer which sorts the ions formed according to their mass to charge ratio (m/z) and - a detector which allows the quantitative analysis of the m/z signals of a sample . Several types of mass spectrometers can be used, and, in the absence of a consensual and standardized method, have practical methods for carrying out different analyzes which also lead to the generation of signals specific to each of them, the nature, the complexity and the completeness of the information contained being heterogeneous. Each type of instrument has advantages and disadvantages in terms of ease of sampling, speed of analysis, completeness of information and technical and analytical constraints for carrying out the analyses. For example, some instruments such as proton transfer reaction mass spectrometers (PTR-MS) or those using soft ionization by chemical transfer reaction (SICRIT) are relevant for perform measurements online and in real time, without storing a sample of exhaled air but vary by their mode of ionization and the resolution of the associated detectors. However, their level of information generated does not generally allow VOCs to be identified (soft ionization, absence of chromatographic separation, etc.). Indeed, once a signature of VOCs (characterized by their m/z) is discovered, their formal chemical identification is then the critical and obligatory step to improve knowledge on the physiology and regulatory processes of VOCs as well as to set up and clinically validate specific quantitative measurement methods based on portable technologies (sensors, etc.). Two-dimensional gas chromatography coupled with mass spectrometry (GCxGC-MS) is the most advanced technology at present for this purpose, combining two chromatographic columns with complementary stationary phases and ionization of VOCs by electron impact before MS detection. Compounds coeluting in conventional gas chromatography can be separated by GCxGC, and several teams have published proof-of-concept studies using GCxGC-MS for breath biomarker discovery for lung cancer diagnosis , tuberculosis or severe asthma phenotyping . One of the main challenges consists in establishing the concordance of the signals generated by the different technological approaches, some employing a preliminary chromatographic separation, others not, and some employing soft ionization methods whereas those of the others are on the contrary hard. Thus, the availability of datasets obtained on the same population with these complementary technological approaches will allow significant progress for the identification of the COVs of interest in clinical studies, beyond the simple comparison of the analytical performances of the different methods.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required.
| Arm | Type | Receives |
|---|---|---|
| Group of healthy volunteers | Other | Other: Three spectrometry differents technicsThis research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Healthy volunteer
- At least 18 years old
- Perfect command of the French language
- Signature of an informed consent form
- Affiliated to a health insurance plan
Key exclusion criteria (4 listed)
- Pregnant women
- People with known pathology(ies)
- Active smoking
- Deprived of liberty or under guardianship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Three spectrometry differents technicsCollection of expired air as follows: * For online mass spectrometry techniques (PTR-MS and SICRIT) * For offline mass spectrometry (GCxGC-MS) Performing volatolome analyses: * By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes * By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes. | Other | Group of healthy volunteers |
Primary outcome
To compare informations obtained by three different spectrometry techniques
Time frame: one day
Compare the information obtained by three mass spectrometry techniques (PTR-MS, SICRIT, GCxGC-MS) for the analysis of volatolome during clinical studies
3 secondary outcomes
1- Compare sampling techniques
Time frame: one day
2-Compare the profile of VOCs
Time frame: one day
Determine the average time needed to perform each type of sample and associated analyzes
Time frame: one day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2025.
- Derived from this study: PubMed 41832327Roquencourt C, Lamy E, Hunzinger N, Salvator H, Devillier P, Bardin E, Grassin-Delyle S. Soft ionization by chemical reaction in transfer-high-resolution mass spectrometry for clinical exhaled breath profiling. Anal Bioanal Chem. 2026 Jun;418(11):3227-3238. doi: 10.1007/s00216-026-06425-1. Epub 2026 Mar 15.
Related trials for Respiratory Disease
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Three spectrometry differents technics in people with Respiratory Disease, run by Hopital Foch at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare informations obtained by three different spectrometry techniques (time frame: one day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06020521, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2025.